Abstract

The interplay between glioma stem cells (GSCs) and the tumor microenvironment plays crucial roles in promoting malignant growth of glioblastoma (GBM), the most lethal brain tumor. However, the molecular mechanisms underlying this crosstalk are incompletely understood. Here, we show that GSCs secrete the Wnt‐induced signaling protein 1 (WISP1) to facilitate a pro-tumor microenvironment by promoting the survival of both GSCs and tumor-associated macrophages (TAMs). WISP1 is preferentially expressed and secreted by GSCs. Silencing WISP1 markedly disrupts GSC maintenance, reduces tumor-supportive TAMs (M2), and potently inhibits GBM growth. WISP1 signals through Integrin α6β1-Akt to maintain GSCs by an autocrine mechanism and M2 TAMs through a paracrine manner. Importantly, inhibition of Wnt/β-catenin-WISP1 signaling by carnosic acid (CA) suppresses GBM tumor growth. Collectively, these data demonstrate that WISP1 plays critical roles in maintaining GSCs and tumor-supportive TAMs in GBM, indicating that targeting Wnt/β-catenin-WISP1 signaling may effectively improve GBM treatment and the patient survival.

The tumour microenvironment plays an important role in promoting glioblastoma. Here, the authors show that glioma stem cells secrete WISP1, which promotes both the survival of the stem cells and tumour-associated macrophages.

Details

Title
Dual Role of WISP1 in maintaining glioma stem cells and tumor-supportive macrophages in glioblastoma
Author
Tao Weiwei 1 ; Chu Chengwei 1 ; Zhou, Wenchao 1 ; Huang, Zhi 1 ; Zhai Kui 1 ; Fang Xiaoguang 1 ; Huang, Qian 1 ; Zhang, Aili 1 ; Wang Xiuxing 2 ; Yu Xingjiang 1 ; Huang, Haidong 1 ; Wu Qiulian 2 ; Sloan, Andrew E 3 ; Yu, Jennifer S 4 ; Li, Xiaoxia 5   VIAFID ORCID Logo  ; Stark, George R 6 ; Rich, Jeremy N 2   VIAFID ORCID Logo  ; Bao Shideng 7   VIAFID ORCID Logo 

 Lerner Research Institute, Cleveland Clinic, Department of Cancer Biology, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725) 
 University of California, San Diego, Division of Regenerative Medicine, Department of Medicine, San Diego, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242) 
 University Hospitals, Case Western Reserve University, Brain Tumor and Neuro-Oncology Center, Seidman Cancer Center, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847) 
 Lerner Research Institute, Cleveland Clinic, Department of Cancer Biology, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847); Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725); Center for Cancer Stem Cell Research, Lerner Research Institute, Cleveland Clinic, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725) 
 Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847); Lerner Research Institute, Cleveland Clinic, Department of Inflammation and Immunity, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725) 
 Lerner Research Institute, Cleveland Clinic, Department of Cancer Biology, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847) 
 Lerner Research Institute, Cleveland Clinic, Department of Cancer Biology, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725); Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847); Center for Cancer Stem Cell Research, Lerner Research Institute, Cleveland Clinic, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2413230772
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.